Inactive Instrument

News Plasmatech Biopharmaceuticals Inc Nasdaq

Stocks

US72754H1095

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06-12	Abeona Therapeutics Inc. Announces Resignation of Michael Amoroso as Member of Board of Directors, Nominating and Corporate Governance Committee, Effective June 11, 2026	CI
06-04	Abeona Therapeutics Inc Participates in Pre-Investigational New Drug Meeting with Fda Regarding Abo-701	CI

All News

Mentions Relevance

06-12	Abeona Therapeutics Inc. Announces Resignation of Michael Amoroso as Member of Board of Directors, Nominating and Corporate Governance Committee, Effective June 11, 2026	CI
06-04	Abeona Therapeutics Inc Participates in Pre-Investigational New Drug Meeting with Fda Regarding Abo-701	CI
06-01	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05-26	Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences	AQ
05-13	Abeona Therapeutics Inc., Q1 2026 Earnings Call, May 13, 2026
05-13	Abeona Therapeutics : Presentation Q1 2026 PDF Q1 2026	PU
05-13	Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Abeona Therapeutics: Q1 Earnings Snapshot	AQ
05-13	Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update	AQ
05-11	Abeona Therapeutics Inc Activates Children's Hospital of Philadelphia as New Qualified Treatment Center for Zevaskyn	CI
05-11	Abeona Therapeutics announces activation of Children's Hospital of Philadelphia as a new qualified treatment center for Zevaskyn	RE
05-11	Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®	AQ
05-04	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05-04	Abeona Therapeutics® Announces Date of First Quarter Financial Results	AQ
05-01	Abeona Therapeutics : reg; Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PU
04-07	Abeona Therapeutics Inc. Appoints Keith A. Goldan as A New Independent Member to Its Board of Directors as Chairman of Audit Committee , Effective as of April 1, 2026	CI
04-07	Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors	AQ
04-06	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04-02	Abeona Therapeutics Inc. Expands Patient Access to ZEVASKYN with Activation of New Qualified Treatment Center in New York	CI
04-02	Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York	AQ
03-17	Abeona Therapeutics Inc., Q4 2025 Earnings Call, Mar 17, 2026
03-17	Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-17	Abeona Therapeutics FY income from operations USD -89.448 million versus Ibes estimate USD -78.4 million	RE
03-17	Abeona Therapeutics: Q4 Earnings Snapshot	AQ
03-17	Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates	AQ